A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy
Gautam Borthakur(The University of Texas MD Anderson Cancer Center), Jörge E. Cortes(The University of Texas MD Anderson Cancer Center)
Cited by 58
Related Papers
Phase I study of sorafenib in patients with refractory or relapsed acute leukemias
|Haematologica|2010|204
Third-line therapy for chronic myeloid leukemia: current status and future directions
|Journal of Hematology & Oncology|2021|115